Abstract
Background
The BEYOND trial found that the addition of bevacizumab (B) to paclitaxel–carboplatin (PC) chemotherapy provided a significant clinical benefit to Chinese patients with metastatic non-squamous non-small-cell lung cancer (NSCLC). This study aimed to evaluate the cost-effectiveness of adding B to first-line PC induction and continuation maintenance therapy from a Chinese perspective.
Methods
A Markov model was developed to estimate the cost and effectiveness of B + PC in the induction and maintenance therapy of patients with metastatic non-squamous NSCLC. Costs were calculated in the Chinese setting, and health outcomes derived from the BEYOND trial were measured as quality-adjusted life years (QALYs). A one-way sensitivity analysis was conducted to explore the impact of various parameters in the study.
Results
The B + PC treatment was more costly ($112,943.40 versus $32,171.43) and more effective (1.07 QALYs versus 0.80 QALYs) compared with the PC treatment. Adding B to the PC regimen for non-squamous NSCLC results in an incremental cost-effectiveness ratio of $299,155.44 per QALY, which exceeded the accepted societal willingness-to-pay threshold ($23,970.00) for China. In the sensitivity analysis, the duration of progression-free survival (PFS) for the B + PC group, the cost of the PFS state for B + PC group and the price of B were considered the most sensitive factors in the model.
Conclusions
The addition of B to first-line PC induction and maintenance therapy was not determined to be a cost-effective strategy for metastatic non-squamous NSCLC in China, even when an assistance program was provided.
Similar content being viewed by others
References
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):10–29.
Bode AM, Dong Z, Wang H. Cancer prevention and control: alarming challenges in China. Natl Sci Rev. 2016;3(1):117–27.
Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19.
Riihimäki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014;86(1):78–84.
Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clin Proc. 2008;83(3):355–67.
Minguet J, Smith KH, Bramlage P. Targeted therapies for treatment of non-small cell lung cancer—recent advances and future perspectives. Int J Cancer. 2016;138(11):2549–61.
Hirsch FR, Bunn AJ. EGFR testing in lung cancer is ready for prime time. Lancet Oncol. 2009;10(5):432–3.
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.
Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase iii study of first-line carboplatin/paclitaxel + bevacizumab or placebo in chinese patients with metastatic or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33(19):2197–204.
Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6(1):84–98.
Leung HW, Chan AL, Muo CH. Cost-effectiveness of gemcitabine + modern radiotherapy in locally metastatic pancreatic cancer. Clin Ther. 2016;38(5):1174–83.
Dedes KJ, Matter-Walstra K, Schwenkglenks M, Pestalozzi BC, Fink D, Brauchli P, et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer. 2009;45(8):1397–406.
Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9(3):235–51.
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line therapy for European patients with metastatic EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Phase III study of afatinib or cisplatin + pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–34.
Ting J, Tien HP, Xiang P, Sugay A, Abdel-Sattar M, Wilson L. Cost-effectiveness and value of information of erlotinib, afatinib, and cisplatin-pemetrexed for first-line therapy of metastatic EGFR mutation-positive non-small-cell lung cancer in the United States. Value Health. 2015;18(6):774–82.
Goulart B, Ramsey SD. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer. Value Health. 2011;14(6):836–45.
Gridelli C, De Marinis F, Maio MD, Ardizzoni A, Belani CP, Cappuzzo F, et al. Maintenance therapy of metastatic non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. Lung Cancer. 2012;76(3):269–79.
Klein R, Wielage R, Muehlenbein C, Liepa AM, Babineaux S, Lawson A, et al. Cost-effectiveness of pemetrexed as first-line maintenance therapy for metastatic nonsquamous non-small cell lung cancer. J Thorac Oncol. 2010;5(8):1263–72.
Kumar G, Woods B, Hess LM, Treat J, Boye ME, Bryden P, et al. Cost-effectiveness of first-line induction and maintenance therapy sequences in non-squamous non-small cell lung cancer (NSCLC) in the U.S. Lung Cancer. 2015;89(3):294–300.
Zeng X, Peng L, Li J, Chen G, Tan C, Wang S, et al. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for metastatic nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system. Clin Ther. 2013;35(1):54–65.
Barnett JC, Alvarez SA, Cohn DE, Leath CR, Myers ER, Havrilesky LJ. Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary therapy of ovarian cancer. Cancer. 2013;119(20):3653–61.
Chan JK, Herzog TJ, Hu L, Monk BJ, Kiet T, Blansit K, et al. Bevacizumab in therapy of high-risk ovarian cancer—a cost-effectiveness analysis. Oncologist. 2014;19(5):523–7.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Zheng, H., Xie, L., Zhan, M. et al. Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer. Clin Transl Oncol 20, 286–293 (2018). https://doi.org/10.1007/s12094-017-1715-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-017-1715-1